Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 4 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1

Conditions

Breast Neoplasms 2Uterine Cervical Neoplasms 1Urologic Neoplasms 1Tobacco Use Cessation 1Smoking Cessation 1Sexuality 1Pleural Effusion, Malignant 1Neuroendocrine Tumors 1Gastrointestinal Neoplasms 1Acute Pain 1

Interventions

Octreotide 4lanreotide 3Everolimus 3Carboplatin 2surufatinib 1pasireotide 1gadoteridol 1gadoterate meglumine 1gadolinium ethoxybenzyl DTPA 1gadodiamide 1gadobutrol 1gadobenic acid 1arginyllysine 1Surveys and Questionnaires 1Sunitinib 1Somatostatin 1Positron Emission Tomography Computed Tomography 1Paclitaxel 1Neuropsychological Tests 1Cisplatin 1Cabergoline 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × Neuroendocrine Tumors × Surveys and Questionnaires × Clear all
NCT03289741 2025-05-09

A Study to Evaluate Patient Experience in the Therapy of Neuroendocrine Tumors Treated With Octreotide Long Acting Release Versus Lanreotide

Memorial Sloan Kettering Cancer Center

Phase 4 Completed
51 enrolled 10 charts
EndocrineNET

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡